BioCentury
ARTICLE | Clinical News

A-101: Ph III SEBK-301 and SEBK-302 data

November 18, 2016 9:17 PM UTC

Top-line data from the identical, double-blind, U.S. Phase III SEBK-301 and SEBK-302 trials in a total of 937 patients with 4 target lesions on the face, trunk and extremities showed that up to 2 appl...

BCIQ Company Profiles

Aclaris Therapeutics Inc.